Evidence map›Paper›PMID 32690655›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2020

Human Hepatitis B Viral Infection Outcomes Are Linked to Naturally Occurring Variants of

Austin M Graves, Francesca Virdis, Eliot Morrison, Miguel Álvaro-Benito, Aly A Khan, Christian Freund, Tatyana V Golovkina, Lisa K Denzin

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. MHC Class II Presentation Is Affected by Polymorphism in theJournal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Austin M GravesChild Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901.ORCID 0000-0002-9891-6919
Francesca VirdisChild Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901.
Eliot MorrisonLaboratory of Protein Biochemistry, Department of Biology, Chemistry and Pharmacy, Free University of Berlin, 14195 Berlin, Germany.
Miguel Álvaro-BenitoLaboratory of Protein Biochemistry, Department of Biology, Chemistry and Pharmacy, Free University of Berlin, 14195 Berlin, Germany.ORCID 0000-0002-6019-3567
Aly A KhanDepartment of Pathology, The University of Chicago, Chicago, IL 60637.
Christian FreundLaboratory of Protein Biochemistry, Department of Biology, Chemistry and Pharmacy, Free University of Berlin, 14195 Berlin, Germany.
Tatyana V GolovkinaDepartment of Microbiology, The University of Chicago, Chicago, IL 60637.ORCID 0000-0002-2924-6747
Lisa K DenzinChild Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901; denzinlk@rutgers.edu.ORCID 0000-0002-0554-4547
Freie Universität Berlin · DERutgers, The State University of New Jersey · USUniversity of Chicago · US

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI CHIEN-MIN KAO · 1985 to 2026
$122.1M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
New retroviral restriction factorR01AI117535 · NIAID · UNIVERSITY OF CHICAGO · PI GOLOVKINA, TATYANA V · 2016 to 2020
$3.2M
New retroviral restriction factorR56AI117535 · NIAID · UNIVERSITY OF CHICAGO · PI GOLOVKINA, TATYANA V · 2021 to 2021
$776k
NCATS NIH HHS UL1 TR000430NCI NIH HHS P30 CA014599NCI NIH HHS P30 CA072720NIAID NIH HHS R01 AI117535NIAID NIH HHS R56 AI117535
6 · The paper itself

Abstract

HLA molecules of the MHC class II (MHCII) bind and present pathogen-derived peptides for CD4 T cell activation. Peptide loading of MHCII in the endosomes of cells is controlled by the interplay of the nonclassical MHCII molecules, HLA-DM (DM) and HLA-DO (DO). DM catalyzes peptide loading, whereas DO, an MHCII substrate mimic, prevents DM from interacting with MHCII, resulting in an altered MHCII-peptide repertoire and increased MHCII-CLIP. Although the two genes encoding DO (

Indexed as

AllelesAntigen PresentationCell Line, TumorHeLa CellsHepatitis BHistocompatibility Antigens Class IIHLA-D AntigensHumansPeptidesPolymorphism, Single NucleotideHistocompatibility Antigens Class IIHLA-D AntigensHLA-DO antigensPeptides

Identifiers

PMID32690655
PMCPMC7415708
OpenAlexW3044354618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.